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Abstract
We investigated changes in regulatory genes, vraS and graR, during
development of vancomycin non-susceptibility in a patient with
methicillin-resistant Staphylococcus aureus who failed therapy and
following in-vitro vancomycin exposure and a subsequent drug-free
growth period. Minimum Inhibitory Concentration (MICs) were
determined and genes sequenced at each stage. After 30 days of
vancomycin exposure, the strain attained maximum MIC (20 mg/
L) and was resistant to all antibiotics. Reversion to vancomycin
susceptibility occurred 21 days after removal. We observed muta-
tions in vraS and graR during non-susceptibly development and
novel stop codons in the reverted strain. Mutations in graR appear
important for development of intermediate susceptibility to
vancomycin. The results suggest that monitoring of vancomycin
therapy could allow earlier change to appropriate agents.
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Vancomycin remains the drug of choice for multidrug resis-
tant methicillin-resistant Staphylococcus aureus (MRSA), but
reports of treatment failures associated with development of
decreased susceptibility have increased [1]. Most reports
involve isolates having increased cell wall production.
Currently, Clinical Laboratory Standards Institute (CLSI)
categorizes S. aureus as vancomycin susceptible (VSSA)
(MIC £ 2 mg/L), vancomycin intermediately-susceptible (VISA)
(4–8 mg/L), and vancomycin-resistant (VRSA) (‡16 mg/L) [2],
whereas European Committee on Antimicrobial Sensitivity
Testing (EUCAST) now use only one breakpoint (‡2 mg/L) to
reﬂect the higher likelihood of treatment failure with such
isolates [1,3]. Whilst the mechanism of increased cell wall
thickness in VISA remains unclear, it has been suggested that
VISA-type non-susceptibility is mediated by mutations in the
regulatory genes vraS and graR [4–7]. However, few studies
have tracked genetic changes during development and loss
of vancomycin non-susceptibility in clinical isolates. We inves-
tigated changes in vraS and graR in parallel with phenotypic
characteristics in an isolate in Hong Kong.
Blood culture from an 86-year-old woman, whose echocar-
diogram revealed a small mass attached to the anterior mitral
leaﬂet, yielded MRSA (vancomycin Minimum Inhibitory Con-
centration (MIC) 1.0 mg/L). Vancomycin therapy at 500 mg/
24 h i.v. for 4 days (trough plasma concentration 9.9 mg/L)
was initiated, followed by 500 mg/12 h for 3 days (trough con-
centration 29.8 mg/L). Further cultures remained positive for
MRSA, with vancomycin MIC reaching 6 mg/L (GRD Etest) by
10 days. Vancomycin was replaced by daptomycin 300 mg/
48 h i.v. for 6 days, increased to 350 mg/48 h for 2 days, and
continued with addition of rifampicin (300 mg) for a further
3 days, but the patient’s condition deteriorated and she died
6 weeks after admission.
Vancomycin MICs were repeated for the isolates by both
agar dilution (AD) [2] and the spiral gradient endpoint
method (SGE) [8]. For the SGE, both the conﬂuent growth
endpoint (EC) and extended trailing endpoint (TEC) were
determined for identiﬁcation of presumptive hVISA [8]. To
determine if continued vancomycin exposure would lead
to further changes in MIC, the day ten isolate and Mu50
were incubated in brain heart infusion (BHI) broth (Oxoid,
Basingstoke, UK) with vancomycin (Sigma-Aldrich, St Louis,
MI, USA) at 50% MIC for 48 h at 37C. The MIC was deter-
mined again, the strain transferred to fresh media, and the
process repeated for 50 days. Stability of non-susceptibility
was investigated by successive transfers into vancomycin-free
broth every 48 h with MIC determination at weekly intervals
until it decreased to <2 mg/L.
DNA was extracted from the initial isolate (Q-VSSA) on
day 4 (Q-hVISA, MIC 2.0), day 6 (Q-VISA, MIC 4.0), day 60
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(Q-VISA-max) and after vancomycin exposure (Q-VISAW)
and regulatory genes vraS and graR ampliﬁed using the fol-
lowing primers: vraS forward 5¢-ATGGAAGTACTTACGTG
AATGA-3¢; reverse 5¢-TCGACACTGCATCTAATGCACG
A-3¢ (1041 bp); graR forward 5¢-GGCCGATTTATTACTTTA
TACAAGCACC–3¢; reverse 5¢-ATCATAATCGATTAG
ACTAATGCCTAACAT–3¢ (672 bp) (K Hiramatsu, personal
communication). The amplicons were sequenced to identify
possible mutations contributing towards non-susceptibility
development and to contrast these genetic changes with
N315, Mu3, Mu50 and Mu50W [4–7,9]. Macro-restriction
analysis of chromosomal DNA with Sma1 and pulsed-ﬁeld
gel electrophoresis (PFGE) was performed [10]. The strain
was characterized by multilocus sequence typing (MLST)
[11]. Presence of mecA was conﬁrmed at each stage and
vanA presence investigated when the MIC exceeded 16 mg/L
[12]. MICs for oxacillin, linezolid, tigecycline, and daptomycin
were determined by Etest.
Growth rates in BHI broth over 12 h, lysostaphin lysis,
and time to positivity of the tube coagulase test, were deter-
mined to investigate relationships between genetic and phe-
notypic changes [13].
During extended vancomycin exposure, the MIC of the
clinical isolate reached 20 mg/L by 30 days, remaining
unchanged until 60 days. Mu50 reached MIC 15 mg/L (Mu50-
max) at 54 days. vanA was absent in Q-VISA-max. The strain
reverted to susceptibility 21 days after removal of vanco-
mycin pressure. EC values were generally similar to AD, but
TEC was considerably higher except for Q-VISA-max
(Table 1).
Genetic analysis revealed changes in amino acids at posi-
tions 278 and 279 in vraS during Q-hVISA development. In
Mu50, there was a change, I5N [6], which was not present
in our isolate. A mutation V15A occurred at Q-VISA, but
reverted by Q-VISA-max, whilst another ﬁve silent mutations
occurred in vraS during the period of MIC increase. In graR,
a change, N197S, occurred at MIC 4 mg/L, paralleling the
change in Mu50 [5,6]. A mutation, L92V, was present in the
Q-VSSA isolate, but reverted during non-susceptibility devel-
opment. Another mutation, D148Q, in graR was noted when
the MIC reached 20 mg/L and remained after reversion.
There were four further silent mutations at Q-VISA-max. In
Q-VISAX, two stop codons each in graR and vraS were
observed (vraS, L278Stop, I279Stop; graR, S210Stop,
E224Stop) (Table 2). In vraS of Mu50X a stop codon was
found (M234SC). PFGE demonstrated indistinguishable pat-
terns for all ﬁve isolates, but the strain differed considerably
from Mu50. MLST revealed the strain to be ST1048.
Oxacillin resistance and mecA were observed throughout
and only Q-VISAW was daptomycin sensitive. Q-VSSA, Q-
VISA and Q-VISAW were susceptible to tigecycline and lin-
ezolid, but Q-VISA-max was resistant to all drugs. Coagula-
tion time increased with non-susceptibility, Q-VISA-max
requiring the longest detection time. Q-VISA-max was also
more resistant to lysostaphin (Table 1). Q-VISA and Q-VISA-
max displayed slower growth rates than Q-VSSA (Fig. 1).
MRSA-infected patients failing to respond to vancomycin
are often prescribed a higher dose to increase the trough
value of the drug [14,15]. Initial dosage for this patient was
low for treatment of endocarditis and may have led to selec-
tion of a resistant mutant due to sub-MIC levels in the valve
vegetation [15]. Continued in vitro vancomycin exposure
resulted in the MIC increasing to a level previously described
as fully resistant [12]. Use of SGE to determine both the EC
and TEC allowed visual identiﬁcation of Q-hVISA during the
increase in non-susceptibility and showed the elimination of
heterogeneity of resistance in the Q-VISA-max population
[8]. TEC colonies with MIC > 2 mg/L were seen in the initial
TABLE 1. MICs to vancomycin and other agents, time to coagulase positivity and loss of viability following lysostaphin
treatment of isolates
Day of
collectiona
Vancomycin
Tigecyclineb Daptomycinb Linezolidb Oxacillinb
Coagulase activity Lysostaphin test
AD
SGE
1:1
(DT)
1:10
(DT)
1:100
(DT)
1:1000
(DT)
1:10000
(DT)
1:100000
(DT)
% loss
of viability
% loss of
viability
EC TEC 40 min 60 min
1 (Q-VSSA) 1 1.2 2.8 0.25 1.5 0.50 >128 0.75 1.00 2.00 8.00 18.00 23.30 58.83 84.60
4 (Q-hVISA) 2 2.8 3.3 6.0 15.00 21:30 – – – 44.14 70.70
5 3 3.7 4.2
6 (Q-VISA) 4 4.2 6.2 0.38 2 0.75 >128 16.0 23:30 – – – – 30.76 56.92
10 6 6.2 7.0
60 (Q-VISA-max) 20 20 20 2.50 3 16.00 >128 23.0 – – – – – 8.08 20.10
81 (Q-VISAW) 2 1.8 1.8 0.38 0.75 0.75 >128 2.0 3.00 5.00 13:00 – – 50.50 77.30
DT, detection time in hours; AD, agar dilution; SGE, spiral gradient endpoint technique; EC, endpoint concentration; TEC, trailing endpoint concentration.
aDays 1–10 were isolated from blood culture, Q-VISA-max and Q-VISAW after induction with vancomycin.
bDetermined by Etest, performed only on change of vancomycin susceptibility category.
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isolate, suggesting potential VISA development. Repeated
MIC determination early in vancomycin therapy could reveal
increases and allow timely change to another agent. Failure
to change early may severely reduce treatment options as,
although cross-resistance to linezolid and tigecycline was
absent at lower MICs, Q-VISA-max was resistant to all drugs
tested. Loss of daptomycin susceptibility [16] and loss of
oxacillin resistance and inability to amplify mecA have been
reported during vancomycin non-susceptibility development
[17]. However, the latter may vary between isolates as the
oxacillin MIC remained unchanged throughout.
The absence of the change I5N in vraS, suggested as
important for h-VISA development [6,18], indicates that this
mutation may not be essential for loss of susceptibility.
Alternatively, the changes in AAs 278 and 279 in vraS in our
isolate, which were sustained throughout non-susceptibility,
may similarly affect the regulatory function of the vraS gene
product. Our study observed the same N197S change in
graR as that reported in Mu50 [5,6], suggesting that this is an
essential step in non-susceptibility development. The L92V
change in our initial isolate may have increased the likelihood
of VISA development as loss of susceptibility occurred rap-
idly, but this will require analysis of further isolates to con-
ﬁrm. The mutation D148Q in graR may be important for
development of high resistance (20 mg/L). This change was
not seen in Mu50, which had a lower MIC (8 mg/L), but has
been reported in other VISA strains [5]. The possible impor-
tance of the vra/gra genes was also revealed by tracking the
whole genome during vancomycin non-susceptibility develop-
ment [19].
Few studies have investigated genetic changes associated
with reversion to susceptibility. Mu50X, isolated from a
patient 18 months after his initial Mu50 infection, was vanco-
mycin susceptible. It had a stop codon in vraS and lost the
mutation in graR, reverting to the VSSA gene conformation
[6]. In contrast, in our revertant, novel mutations in both
vraS and graR resulted in stop codons in both genes. This
suggests an adaptation for rapid correction, allowing reduc-
tion of cell wall synthesis. It is possible that eventually there
may be loss of the graR mutation, as occurred in Mu50X [6].
Loss of non-susceptibility resulted in restored susceptibility
to daptomycin, and reduced MICs for other drugs.
Changes in time to coagulase positivity and lysostaphin
lysis resistance paralleled the changes in vancomycin MIC
TABLE 2. Comparison of vraS and graR sequences
Stage
Gene vraS graR
Position
NN 13–5 700–2 832–4 835–7 274–6 589–91 628–30 670–2
AA 5 234 278 279 92 197 210 224
VSSA N315 NN ATT ATG TTT AAT CTT AAT AGT GAA
AA I M F N L N S E
Q-VSSA NN ATT ATG TTT AAT GTT AAT AGT GAA
AA I M F N V N S E
hVISA Mu3 NN AAT ATG TTT AAT CTT AAT AGT GAA
AA N M F N L N S E
Q-hVISA NN ATT ATG TTA ATA GTT AAT AGT GAA
AA I M L I V N S E
VISA Mu50 NN AAT ATG TTT ATG CTT AGT AGT GAA
AA N M F M L S S E
Q-VISA (Sequence
ended at 528)
NN ATT – – – CTT AGT AGT GAA
AA I – – – L S S E
VISAmax Mu50-max NN AAT ATG TTT ATG CTT AGT AGT GAA
AA N M F M L S S E
Q-VISA-max NN ATT ATG TTA ATA CTT AGT AGT GAA
AA I M L I L S S E
VISAW Mu50W NN AAT TGA TTA ATA CTT AAT AGT GAA
AA N SC L I L N S E
Q-VISAW NN ATT ATG TAA TAA CTT AGT TAG TGA
AA I M SC SC L S SC SC
SC = stop codon.
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FIG. 1. Comparison of growth rates at different stages of non-sus-
ceptibility to vancomycin.
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with rapid reversion to initial values in the X isolate. These
effects were similar to those previously described and
reﬂected changes in cell wall thickness [13].
In summary, this study supports the proposition that
mutations in vraS/graR may be important for development of
non-susceptibility. There was a common mutation (N197S)
in graR found in both our isolate and Mu50. Removal of
vancomycin pressure led to the presence of stop codons in
both genes, which seems to lead to rapid loss of non-suscep-
tibility. It must be noted that this study has focused on
changes in only two genes and therefore may have missed
changes in other genes important in the control of cell wall
synthesis [19,20]. Differences in mutations in both develop-
ment and reversion of vancomycin non-susceptibility
observed between this study and other reports suggest the
need for further investigation of genetic determinants con-
trolling non-susceptibility.
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b-lactamase-producing clone with a hetero-
geneous carbapenem resistance phenotype
S. Pollini1, E. Fiscarelli2, C. Mugnaioli1, V. Di Pilato1,
G. Ricciotti2, A. S. Neri3 and G. M. Rossolini1,4
1) Universita` degli Studi di Siena, Siena, 2) Ospedale Pediatrico Bambino
Gesu`, Rome, 3) Universita` degli Studi di Firenze, Florence and 4) Azienda
Ospedaliera-Universitaria Senese, Siena, Italy
Abstract
An epidemic IMP-13 metallo-b-lactamase (MBL)-producing Pseu-
domonas aeruginosa clone, causing infections and even large
outbreaks in Italian critical care settings, was detected in a
young cystic ﬁbrosis patient. In this patient, the chronic infec-
tion was sustained by distinct clonal sub-populations of the
MBL-producing P. aeruginosa clone, either susceptible or resis-
tant to carbapenems. These ﬁndings underscore the impor-
tance of infection prevention practices in cystic ﬁbrosis
settings and pose an important diagnostic and therapeutic
challenge.
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Pseudomonas aeruginosa is a major pathogen for patients with
end-stage chronic obstructive pulmonary disease, including
patients with cystic ﬁbrosis (CF) [1], in whom it establishes a
persistent respiratory infection with recurrent exacerbations
[2].
P. aeruginosa is prone to acquire antibiotic resistance and
multidrug resistant (MDR) clones represent an important
therapeutic challenge [1]. In CF patients, infection by MDR
P. aeruginosa clones has been associated with a more severe
prognosis [3], and cross-contamination with similar clones is
a matter of major concern [4].
Acquired metallo-b-lactamases (MBLs) are emerging resis-
tance determinants of increasing clinical importance. MBLs
can confer a very broad spectrum of resistance to b-lactams
(including the expanded-spectrum cephalosporins and carba-
penems), which is not reversible by the available b-lactamase
inhibitors. Due to linkage of MBL genes with other resistance
genes, MBL-producing strains usually exhibit a complex MDR
phenotype [5]. MBL-producing P. aeruginosa have been
reported worldwide in nosocomial settings, sometimes caus-
ing major outbreaks [5]. However, their presence in CF
patients has not been reported, except for a single report in
Portugal [6].
In this paper we demonstrate the acquisition of an MBL-
producing epidemic P. aeruginosa clone in a CF patient; the
MBL-producing strain caused a chronic infection that was
sustained by distinct clonal sub-populations with a different
carbapenem resistance phenotype.
A female CF patient, monitored at a paediatric hospital in
Rome (Italy), was ﬁrst colonized by an MDR P. aeruginosa at
the age of 6 years and subsequently developed a chronic
infection. Before infection by P. aeruginosa, the patient had
received prophylaxis with aerosolized tobramycin and
azithromycin (since the ages of 6 months and 5 years,
respectively), and had occasionally received expanded-spec-
trum cephalosporins and ciproﬂoxacin. In the 6-year follow-
up period after P. aeruginosa infection, the patient presented
with several episodes of acute exacerbations (average 2 per
year), with a progressive decline of FEV1 (61% at the end of
the follow-up period), and received intermittent inhaled tob-
ramycin and azithromycin therapy; exacerbation episodes
were treated with ciproﬂoxacin, expanded-spectrum cepha-
losporins and, only in one case, with carbapenems.
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